Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

NCT ID: NCT00724386

Last Updated: 2014-03-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-06-30
• Study Completion Date: 2012-11-30

Brief Summary

The goal of this study is to determine the feasibility based on toxicity and response rate of giving paclitaxel weekly with concomitant every-other week radiotherapy to limit skin toxicity. This study will also seek to determine the maximally tolerated dose of Navelbine added to this combination when followed by Filgrastim and the dose-limiting toxicities of this regimen.

Conditions

Breast Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Paclitaxel

1-hour IV infusion once weekly for 12 to 14 weeks

Intervention Type: DRUG

Vinorelbine

escalating doses administered intravenously over 6-10 minutes for 12-14 weeks

Intervention Type: DRUG

Filgrastim

daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).

For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject

Intervention Type: DRUG

Radiation

Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy

Intervention Type: RADIATION

Other Intervention Names

Taxol; Navelbine

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed adenocarcinoma of the male or female breast (male or female) with gross, uncontrolled, unresectable breast and/or chest wall disease including:

1. patients with locally advanced unresectable stage IIIa or IIIb;

2. patients with locally recurrent (including locoregional lymph nodes) disease for which curative surgery is not thought possible

3. patients with metastatic disease AND uncontrolled locoregional disease are eligible.

• Prior chemotherapy allowed, except for nitrosoureas and mitomycin chemotherapy or high dose chemotherapy with marrow or stem cell rescue.
• Prior palliative radiation to sites of metastases allowed (i.e. bone, brain, lung)
• 4 weeks since any prior treatments (excluding hormonal therapy). Concurrent hormonal therapy is not allowed.
• Aged 18 years or older
• CALGB performance status of 0 - 2
• Life expectance of at least 12 weeks
• Initial Laboratory Data:

• ANC Count > 1500/mm3
• Platelet Count > 100,000/mm3
• Creatine ≤ 2.0 mg/dl
• Bilirubin ≤ 1.5 mg/dl
• ALT (SGPT) ≤ 3 times the upper limit of normal
• Signed informed consent

Exclusion Criteria

• Prior breast or chest wall radiation is not allowed unless the proposed site radiation port does not overlap with prior ports
• Subjects must not be pregnant (females able to have children must have negative pregnancy test and agree to use adequate contraception)
• Patients with a documented hypersensitivity to E.coli derived proteins are excluded.
• No other serious medical condition such as uncontrolled infection that in the opinion of the investigators places patient at undue risk for study treatment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: collaborator

University of Chicago

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Chicago

Chicago, Illinois, United States

Countries

United States

Other Identifiers

UCIRB 9849

Identifier Type: -

Identifier Source: org_study_id